Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS
J Clin Oncol. 2008 26 (14): 2292-8

PMID: 18467720 · PMCID: PMC3724516 · DOI:10.1200/JCO.2007.13.3165

MeSH Terms (18)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Cancer Vaccines Combined Modality Therapy Dose-Response Relationship, Drug Female Freund's Adjuvant gp100 Melanoma Antigen HLA-A2 Antigen Humans Interleukin-2 Male Mannitol Melanoma Membrane Glycoproteins Middle Aged Oleic Acids

Connections (1)

This publication is referenced by other Labnodes entities: